{"id":"NCT01202227","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain","officialTitle":"An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2010-09-15","resultsPosted":"2013-05-17","lastUpdate":"2021-01-28"},"enrollment":104,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Spinal Cord Diseases","Spinal Cord Injuries","Neuralgia","Pain"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":[]}],"arms":[{"label":"Pregabalin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).","primaryOutcome":{"measure":"Number of Participants With Peripheral Edema","timeFrame":"Baseline, Weeks 4, 20, 36, 52, and 53","effectByArm":[{"arm":"Pregabalin","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":26,"countries":["Japan"]},"refs":{"pmids":["25114584"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081252&StudyName=An%20Open-Label%20Long-Term%20Study%20Of%20Pregabalin%20For%20The%20Treatment%20Of%20Central%20Neuropathic%20Pain"]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":103},"commonTop":["Somnolence","Weight increased","Nasopharyngitis","Dizziness","Oedema peripheral"]}}